Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Sign Up to like & getrecommendations! Published in 2017 at "The Lancet"
DOI: 10.1016/s0140-6736(17)30550-0
Abstract: BACKGROUND IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-20 years. In… read more here.
Keywords: trial; iga nephropathy; trf budesonide; placebo ... See more keywords
Are we ready for targeted therapy for IgA nephropathy?
Sign Up to like & getrecommendations! Published in 2017 at "The Lancet"
DOI: 10.1016/s0140-6736(17)30820-6
Abstract: Almost 50 years have passed since the initial description of IgA nephropathy by Berger and Hinglais. IgA nephropathy is the most common chronic glomerulonephritis in the world. A renal biopsy is required for diagnosis but… read more here.
Keywords: iga nephropathy; ready targeted; iga; treatment ... See more keywords
Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.926517
Abstract: Immunoglobulin A (IgA) nephropathy is a common autoimmune kidney disease. Accumulating studies showed that IgA nephropathy may be partially correlated with mucosal immune system dysfunction. Systemic corticosteroid treatment exerts an essential protective effect against renal… read more here.
Keywords: review; iga nephropathy; targeted release; trf budesonide ... See more keywords